Organon (OGN) Reports Q1 Net Loss of $11.8M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Organon (OGN) Reports Q1 Net Loss of $11.8M

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 17, 2022 1:00 AM EDT


-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22-

-Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial-

-Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States-


Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
                


... More